Oct 3 (Reuters) - Chinese biotech companies WuXi AppTec

and WuXi Biologics ( WXIBF ), which are being

targeted by a forthcoming U.S. national security legislation,

are working on sales of some of their operations, the Financial

Times reported on Thursday, citing people familiar with the

matter.

WuXi AppTec has put its cell and gene therapy manufacturing

arm WuXi Advanced Therapies, which operates four laboratories

and manufacturing facilities in Philadelphia, up for sale, the

newspaper reported.

WuXi Biologics ( WXIBF ) is also working with advisers to test

interest in some of its European production facilities, FT

reported, citing three people familiar with the situation.